News Column

OPKO HEALTH, INC. FILES (8-K) Disclosing Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

June 17, 2014

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 12, 2014, OPKO Health, Inc. (the "Company") held its 2014 Annual Meeting of Stockholders (the "Annual Meeting"). Below is a summary of the proposals and corresponding votes.

1. All ten nominees were elected to the Board of Directors with each director receiving votes as follows: Election of Directors For Withheld Phillip Frost, M.D. 252,308,561 14,282,289 Jane H. Hsiao, Ph.D. 247,732,542 18,858,308 Steven D. Rubin 245,882,802 20,708,048 Robert A. Baron 263,825,181 2,765,669 Thomas E. Beier 255,927,907 10,662,943 Dmitry Kolosov 264,542,320 2,048,530 Richard A. Lerner, M.D. 264,415,310 2,175,540 John A. Paganelli 255,991,073 10,599,777 Richard C. Pfenniger, Jr. 264,345,443 2,245,407 Alice Lin-Tsing Yu, M.D., Ph.D. 246,350,609 20,240,241 2. The approval, on a non-binding advisory basis, of the compensation of the named executive officers of the Company ("Say On Pay") as disclosed in the Company's Proxy Statement for the 2014 Annual Meeting of Stockholders, pursuant to the compensation disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the compensation tables, and any related information found in the proxy statement. The votes on this proposal were as follows: For Against Abstain 255,718,117 10,177,027 569,599

There were no broker non-votes for either proposal. No other matters were considered or voted upon at the Annual Meeting.

ITEM 7.01. Regulation FD Disclosure.

On June 12, 2014, the Company held its Annual Meeting of Stockholders. Copies of the Company's Renal, Diagnostics, and API Division's presentations presented at the Annual Meeting are furnished with this Current Report on Form 8-K as Exhibits 99.1, 99.2, and 99.3, respectively.

Statements made in the presentations which are not historical are forward-looking statements that reflect management's current views with respect to future events and performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Such statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The fact that these presentation materials are being furnished should not be deemed an admission as to the materiality of any information contained in the materials.

The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibits 99.1, 99.2, and 99.3 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Act, unless expressly stated otherwise.


ITEM 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit Number Description 99.1 Renal Division Presentation - 2014 Annual Meeting of Stockholders held June 12, 2014. 99.2 Diagnostics Division Presentation - 2014 Annual Meeting of Stockholders held June 12, 2014. 99.3 API Division Presentation - 2014 Annual Meeting of Stockholders held June 12, 2014.


For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters